| P50 | author | Richard A. Larson | Q41899936 |
| | Koen van Besien | Q43263315 |
| P2093 | author name string | Yanming Zhang | |
| | Lucy A Godley | |
| | Olatoyosi Odenike | |
| | Wendy Stock | |
| | Dezheng Huo | |
| | Margaret Green | |
| | Andrew Artz | |
| | Sandeep Gurbuxani | |
| | Elizabeth Hyjek | |
| | Devika Gajria | |
| | Dorothy Sipkins | |
| | Nicholas P Campbell | |
| | Sarah M Larson | |
| | Christopher Daugherty | |
| | Howie Weiner | |
| | Michael Thirman | |
| P2860 | cites work | Measuring comorbidity in older cancer patients | Q30482056 |
| | Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant | Q33390055 |
| | Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995) | Q33758413 |
| | Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study | Q33770347 |
| | Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine | Q33841988 |
| | A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome | Q33843955 |
| | Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. | Q34049208 |
| | P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808 | Q34124919 |
| | High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902. | Q34500856 |
| | 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline | Q34523108 |
| | Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study | Q34528336 |
| | A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group | Q34542232 |
| | Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis | Q34555592 |
| | Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials | Q34608688 |
| | Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia | Q34615081 |
| | Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia | Q40543180 |
| | Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors | Q43212283 |
| | High remission rate in acute myeloblastic leukemia with only two days of chemotherapy | Q43621662 |
| | Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial | Q43622754 |
| | High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia | Q43666906 |
| | Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial | Q43718516 |
| | Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinosi | Q44010377 |
| | Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. | Q45245159 |
| | The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis | Q46580597 |
| | The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. | Q54629037 |
| | Poor prognosis acute myelogenous leukemia: 1 – response to treatment with high dose cytarabine/mitoxantrone/ethyol @ (Amifostine) | Q59315448 |
| P433 | issue | 3 | |
| P921 | main subject | leukemia | Q29496 |
| | cytarabine | Q180983 |
| | acute myeloid leukemia | Q264118 |
| P304 | page(s) | 445-450 | |
| P577 | publication date | 2012-03-01 | |
| P1433 | published in | Leukemia & Lymphoma | Q6534493 |
| P1476 | title | High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML). | |
| P478 | volume | 53 | |